Recce Pharma heading closer to full efficacy data for flagship R327
Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial has been dosed.
LGD
0.00%
30.0¢
LEGEND CORPORATION LIMITED - Corporate Spotlight
Currently unlisted.
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.